Boston Scientific (BSX) Q3 Sales $5.14B; Cuts FY26 Outlook

What happened

Boston Scientific reported third-quarter 2026 net sales of $5.14B, GAAP EPS of $0.40 and adjusted EPS of $0.73. The company cut its full-year 2026 outlook and guided fourth-quarter sales down about 1% to 3%.

Confirmed

Global impact / market context

A lower full-year outlook means Boston Scientific expects less sales growth and slightly lower adjusted profit per share than before, which can reduce the earnings investors expect and make the stock look less attractive relative to its price.

Analyst inference

The results follow a cybersecurity disruption, and the company points to subdued growth with a weaker fourth-quarter sales guide. That setup puts pressure on management to show recovering procedure volumes and contained incident costs, which means the added expenses tied to the cyber event.

Analyst inference

What to watch

1. Fourth-quarter sales are guided to fall about 1% to 3%, with adjusted EPS of $0.77 to $0.79, so the actual figures will show whether the near-term decline is as steep as guided. Confirmed
2. Watch whether sales volumes recover from the cyber disruption, because faster recovery would lift revenue and help offset the costs and lost business tied to the incident. Analyst inference
3. Track any clearer disclosure of cybersecurity incident costs and mitigation steps, since containing those expenses would protect profit per sale and support the trimmed full-year earnings outlook. Proposed

Evidence

• Original source link unavailable